[go: up one dir, main page]

DK3272343T3 - Tapentadol til hindring og behandling af depression og angst - Google Patents

Tapentadol til hindring og behandling af depression og angst Download PDF

Info

Publication number
DK3272343T3
DK3272343T3 DK17185830.1T DK17185830T DK3272343T3 DK 3272343 T3 DK3272343 T3 DK 3272343T3 DK 17185830 T DK17185830 T DK 17185830T DK 3272343 T3 DK3272343 T3 DK 3272343T3
Authority
DK
Denmark
Prior art keywords
tapentadol
anxiety
depression
prevention
treatment
Prior art date
Application number
DK17185830.1T
Other languages
English (en)
Inventor
Ulrich Jahnel
Ilona Steigerwald
Thomas Tzschentke
Original Assignee
Gruenenthal Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gruenenthal Gmbh filed Critical Gruenenthal Gmbh
Application granted granted Critical
Publication of DK3272343T3 publication Critical patent/DK3272343T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/135Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/06Antimigraine agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Dermatology (AREA)
  • Anesthesiology (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DK17185830.1T 2011-04-29 2012-04-27 Tapentadol til hindring og behandling af depression og angst DK3272343T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP11003508 2011-04-29
EP12720794.2A EP2701693B1 (en) 2011-04-29 2012-04-27 Tapentadol for preventing and treating depression and anxiety

Publications (1)

Publication Number Publication Date
DK3272343T3 true DK3272343T3 (da) 2020-04-27

Family

ID=44260882

Family Applications (2)

Application Number Title Priority Date Filing Date
DK12720794.2T DK2701693T3 (da) 2011-04-29 2012-04-27 Tapentadol til hindring og behandling af depression og angst
DK17185830.1T DK3272343T3 (da) 2011-04-29 2012-04-27 Tapentadol til hindring og behandling af depression og angst

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DK12720794.2T DK2701693T3 (da) 2011-04-29 2012-04-27 Tapentadol til hindring og behandling af depression og angst

Country Status (15)

Country Link
US (3) US20120277319A1 (da)
EP (3) EP3656380A1 (da)
JP (3) JP6014655B2 (da)
CY (2) CY1119586T1 (da)
DK (2) DK2701693T3 (da)
ES (2) ES2646363T3 (da)
HR (2) HRP20171570T1 (da)
HU (2) HUE049308T2 (da)
LT (2) LT2701693T (da)
NO (1) NO2701693T3 (da)
PL (2) PL2701693T3 (da)
PT (2) PT3272343T (da)
RS (2) RS56523B1 (da)
SI (2) SI3272343T1 (da)
WO (1) WO2012146383A1 (da)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10361596A1 (de) 2003-12-24 2005-09-29 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
DE102005005446A1 (de) 2005-02-04 2006-08-10 Grünenthal GmbH Bruchfeste Darreichungsformen mit retardierter Freisetzung
DE102004032049A1 (de) 2004-07-01 2006-01-19 Grünenthal GmbH Gegen Missbrauch gesicherte, orale Darreichungsform
DE102005005449A1 (de) 2005-02-04 2006-08-10 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
EP2997965B1 (en) 2009-07-22 2019-01-02 Grünenthal GmbH Tamper-resistant dosage form for oxidation-sensitive opioids
AR087359A1 (es) 2011-07-29 2014-03-19 Gruenenthal Gmbh Tableta a prueba de alteracion que proporciona liberacion inmediata del farmaco
EA201400172A1 (ru) 2011-07-29 2014-06-30 Грюненталь Гмбх Устойчивая к разрушению таблетка, которая обеспечивает немедленное высвобождение лекарственного средства
US10813630B2 (en) 2011-08-09 2020-10-27 Corquest Medical, Inc. Closure system for atrial wall
US10314594B2 (en) 2012-12-14 2019-06-11 Corquest Medical, Inc. Assembly and method for left atrial appendage occlusion
US10307167B2 (en) 2012-12-14 2019-06-04 Corquest Medical, Inc. Assembly and method for left atrial appendage occlusion
US20140142689A1 (en) 2012-11-21 2014-05-22 Didier De Canniere Device and method of treating heart valve malfunction
KR20160031526A (ko) 2013-07-12 2016-03-22 그뤼넨탈 게엠베하 에틸렌-비닐 아세테이트 중합체를 함유하는 템퍼 내성 투여형
EP2845625A1 (en) * 2013-09-04 2015-03-11 Grünenthal GmbH Tapentadol for use in the treatment of fibromyalgia and chronic fatigue syndrome
US9566443B2 (en) 2013-11-26 2017-02-14 Corquest Medical, Inc. System for treating heart valve malfunction including mitral regurgitation
BR112016010482B1 (pt) 2013-11-26 2022-11-16 Grünenthal GmbH Preparação de uma composição farmacêutica em pó por meio de criomoagem
US10842626B2 (en) 2014-12-09 2020-11-24 Didier De Canniere Intracardiac device to correct mitral regurgitation
PT3302454T (pt) * 2015-05-26 2021-04-01 Technophage Investig E Desenvolvimento Em Biotecnologia Sa Composições para utilização no tratamento da doença de parkinson e distúrbios associados
JP2018526414A (ja) 2015-09-10 2018-09-13 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング 乱用抑止性の即放性製剤を用いた経口過剰摂取に対する保護
US10292948B2 (en) * 2017-01-11 2019-05-21 Torrent Pharmaceuticals Limited Tapentadol nasal composition

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4612008A (en) 1983-05-11 1986-09-16 Alza Corporation Osmotic device with dual thermodynamic activity
US4783337A (en) 1983-05-11 1988-11-08 Alza Corporation Osmotic system comprising plurality of members for dispensing drug
US4765989A (en) 1983-05-11 1988-08-23 Alza Corporation Osmotic device for administering certain drugs
DE4426245A1 (de) 1994-07-23 1996-02-22 Gruenenthal Gmbh 1-Phenyl-3-dimethylamino-propanverbindungen mit pharmakologischer Wirkung
PE20030527A1 (es) 2001-10-24 2003-07-26 Gruenenthal Chemie Formulacion farmaceutica con liberacion retardada que contiene 3-(3-dimetilamino-1-etil-2-metil-propil) fenol o una sal farmaceuticamente aceptable del mismo y tabletas para administracion oral que la contienen
ATE458491T1 (de) 2005-08-26 2010-03-15 Univ Leland Stanford Junior Verfahren zur behandlung von kopfschmerzen durch verabreichung von oxytocin
WO2007088473A2 (en) 2006-02-03 2007-08-09 Neurocure Ltd Treatment and prevention of depression with pain, depression secondary to pain, and of neuropathic pain
MX2008013828A (es) 2006-04-28 2008-11-10 Gruenenthal Gmbh Combinacion farmaceutica que comprende 3-(3-dimetilanimo-1-etil-2- metil-propil)-fenol y un nsaid.
DE102007012165A1 (de) 2007-03-12 2008-09-18 Grünenthal GmbH Verwendung von 1-Phenyl-3-dimethylamino-propanverbindungen zur Therapie des Neuropathieschmerzes
EP1985292A1 (en) 2007-04-23 2008-10-29 Grünenthal GmbH Titration of tapentadol
BRPI0819451A2 (pt) 2007-11-23 2017-10-03 Protect Pharmaceutical Corp Composição farmacêutica, método para tratar dor, kit farmacêutico, e, uso de uma composição
WO2009082039A1 (en) * 2007-12-26 2009-07-02 Eisai R & D Management Co., Ltd. Ampa receptor antagonists for epilepsy, mental disorders or deficits in sensory organ
US7872046B2 (en) 2008-01-25 2011-01-18 Xenoport, Inc. Crystalline form of a (3S)-aminomethyl-5-methyl-hexanoic acid prodrug and methods of use
US7868043B2 (en) 2008-01-25 2011-01-11 Xenoport, Inc. Mesophasic forms of (3S)-aminomethyl-5-methyl-hexanoic acid prodrugs and methods of use
WO2010100477A2 (en) 2009-03-03 2010-09-10 Shire Llc Amino acid and peptide carbamate prodrugs of tapentadol and uses thereof
KR20170005189A (ko) 2009-04-30 2017-01-11 그뤼넨탈 게엠베하 류마티스성 통증을 치료하기 위한 1―페닐―3―디메틸아미노프로판 화합물의 용도
FR2970261B1 (fr) 2011-01-10 2013-05-03 IFP Energies Nouvelles Procede d'hydrotraitement de charges lourdes d'hydrocarbures avec des reacteurs permutables incluant au moins une etape de permutation progressive
JP2014510759A (ja) 2011-04-05 2014-05-01 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング 疼痛の慢性化を予防するためのタペンタドール

Also Published As

Publication number Publication date
EP3272343A1 (en) 2018-01-24
JP2014516935A (ja) 2014-07-17
LT2701693T (lt) 2017-11-10
EP2701693A1 (en) 2014-03-05
US20150018426A1 (en) 2015-01-15
US20170196822A1 (en) 2017-07-13
NO2701693T3 (da) 2018-01-20
RS60152B1 (sr) 2020-05-29
JP6014655B2 (ja) 2016-10-25
SI2701693T1 (sl) 2017-11-30
US9980927B2 (en) 2018-05-29
JP2018021053A (ja) 2018-02-08
EP2701693B1 (en) 2017-08-23
CY1119586T1 (el) 2018-03-07
JP6445637B2 (ja) 2018-12-26
DK2701693T3 (da) 2017-11-13
ES2646363T3 (es) 2017-12-13
JP2017031182A (ja) 2017-02-09
HRP20200600T1 (hr) 2020-10-16
PT2701693T (pt) 2017-11-16
HRP20171570T1 (hr) 2017-11-17
RS56523B1 (sr) 2018-02-28
HUE034003T2 (en) 2018-02-28
SI3272343T1 (sl) 2020-06-30
WO2012146383A1 (en) 2012-11-01
LT3272343T (lt) 2020-05-11
PL3272343T3 (pl) 2020-07-27
US20120277319A1 (en) 2012-11-01
ES2788548T3 (es) 2020-10-21
EP3656380A1 (en) 2020-05-27
PL2701693T3 (pl) 2018-01-31
PT3272343T (pt) 2020-04-23
EP3272343B1 (en) 2020-02-12
CY1123051T1 (el) 2021-10-29
HUE049308T2 (hu) 2020-09-28

Similar Documents

Publication Publication Date Title
DK3272343T3 (da) Tapentadol til hindring og behandling af depression og angst
HK1255283A1 (zh) 用於治療流感的化合物和方法
DK3378862T3 (da) Dihydropyrimidinoisoquinolinoner og farmaceutiske sammensætninger deraf til behandlingen af multipel sklerose
DK2898061T3 (da) Probiotiske sammensætninger til behandlingen af fedme og fedme-relaterede tilstande
DK2935303T3 (da) 4`-fluornukleosider, 4`-fluornukleotider og analoger dertil til behandling af HCV
DK3444342T3 (da) Fremgangsmåder og sammensætninger til behandlingen af lysosomale aflejringssygdomme
HUE044123T2 (hu) Csepegtetõ készülék és eljárás
DK2714135T3 (da) Medikamentadministrationsanordning og fremgangsmåde til styring af anordningen
DK2914627T3 (da) Anti-cd40-antistoffer og fremgangsmåder til anvendelse
DK3238709T3 (da) Forbedrede parenterale formuleringer af lipofile farmaceutiske midler og fremgangsmåder til fremstilling og anvendelse af samme
DK2704703T3 (da) Transdermale sammensætninger af ibuprofen og fremgangsmåder til anvendelse deraf
DK2694091T3 (da) Fremgangsmåde til fremstilling af kompakte tale-nukleaser og anvendelse heraf
DK2804587T3 (da) Formulering og fremgangsmåde til øgning af lægemidlers biotilgængelighed
DK2841097T3 (da) Sammensætninger og fremgangsmåder til behandling og forebyggelse af porcint reproduktions- og respirationssyndrom
DK2764459T3 (da) Fremgangsmåder og processer til ikke-invasiv bedømmelse af genetiske variationer
DK3556774T3 (da) Anti-CD40-antistoffer og anvendelser deraf
DK2739293T3 (da) Fremgangsmåder og sammensætninger til frembringelse af vaccinavirus
DK2632954T4 (da) Midler og fremgangsmåder til behandling af dlbcl
DK2919923T3 (da) Holder-sortiment og rengøringsapparater til rengøring af åndedrætsapparater
DK2688557T3 (da) Fremgangsmåder og sammensætninger til behandling af forstyrelse af opmærksomhed
DK2815769T3 (da) Fam19a5 til anvendelse i diagnosticering og behandling af skader på centralnervesystemet
DK3141548T3 (da) Fremgangsmåder og mellemprodukter til fremstilling af azaindoler
DK2917231T3 (da) Lipopeptider til anvendelse ved behandling af leversygdomme og hjerte-kar-sygdomme
DK2627656T3 (da) Fremgangsmåde til fremstilling af dihydropteridinon og intermediater deraf
DK2702992T3 (da) Anvendelse af melatonin til behandling af og/eller forebyggelse af mucositis